Grammer, AC, MM Ryals, MD Catalina and PE Lipsky. Repositioning drugs for SLE. Systemic Lupus Erythematosus 2016: 567-573.
Lipsky PE, Ryals M, Grammer AC. A Novel Strategy to Identify and Evaluate Approved Drugs & Treatments for Repositioning as Therapies for Systemic Lupus Erythematosus (SLE). American College of Rheumatology 2014, A6 74.
A comprehensive approach to identify approved drugs & treatments for repositioning as therapies for systemic lupus erythematosus.
Grammer AC et al. Arthritis Research & Therapy. 2014
Increased frequency of a unique spleen tyrosine kinase (Syk) bright memory B-cell population in systemic lupus erythematosus.
Fleischer SJ, et al. Arthritis Rheumatol. 2014
Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus.
Wu XN, et al. Sci Transl Med. 2014
The TRIFRA trial: efforts employed to minimise expectation bias.
Ann Rheum Dis. 2014 Nov
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.
Lipsky PE, et al. Arthritis Res Ther. 2014
Tissue distribution and dependence of responsiveness of human antigen-specific memory B cells.
Giesecke C, et al. J Immunol. 2014
B cells: depletion or functional modulation in rheumatic diseases.
Dörner T, et al. Curr Opin Rheumatol. 2014
Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus.
Shirota Y, et al. Ann Rheum Dis. 2013
Molecular characterization of circulating plasma cells in patients with active systemic lupus erythematosus.
Lugar PL, et al. PLoS One. 2012